Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

YUMANITY THERAPEUTICS, INC.

(YMTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Yumanity Therapeutics, Inc.
Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The CompanyÔÇÖs pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Number of employees : 44 people.
Sales per Business
20192020Delta
Treatments for Neurodegenerative Diseases5.00100%6.90100% +37.92%
USD in Million
Sales per region
20192020Delta
United States5.00100%6.90100% +37.92%
USD in Million
Managers
Name Title Age Since
Richard Peters, Dr. President, CEO, Secretary, Treasurer & Director 58 2020
Marie N. Epstein Vice President-Finance - 2020
Brigitte Robertson, Dr. Chief Medical Officer - -
Ajay Verma, Dr. Executive VP, Head-Research & Development - 2021
Daniel Tardiff, Dr. Research Head - -
Patricia L. Allen Independent Director 58 2020
David A. Arkowitz Independent Director 58 2019
Kimberlee Cobleigh Drapkin Independent Director 52 2019
Richard A. Heyman, Dr. Independent Director 62 -
Jeffery W. Kelly, Dr. Independent Director 59 2006
Members of the board
Name Title Age Since
N. Anthony Coles, Dr. Non-Executive Chairman 60 2021
Richard Peters, Dr. President, CEO, Secretary, Treasurer & Director 58 2020
Patricia L. Allen Independent Director 58 2020
David A. Arkowitz Independent Director 58 2019
Kimberlee Cobleigh Drapkin Independent Director 52 2019
Richard A. Heyman, Dr. Independent Director 62 -
Jeffery W. Kelly, Dr. Independent Director 59 2006
Cecil B. Pickett, Dr. Independent Director 74 -
Lynne Zydowsky Independent Director 61 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 10,202,506 8,822,713 86.5% 0 0.0% 86.5%
Shareholders
NameEquities%
Fidelity Management & Research Co. LLC 1,186,089 11.6%
Susan L. Lindquist /Estate Of/ 1,184,561 11.6%
Alexandria Venture Investments LLC 773,236 7.58%
N. Anthony Coles 742,559 7.28%
Redmile Group LLC 611,003 5.99%
Merck & Co., Inc. 526,999 5.17%
Stonepine Capital Management LLC 335,745 3.29%
The Vanguard Group, Inc. 291,267 2.85%
NEA Management Co. LLC 277,839 2.72%
Wellington Management Co. LLP 242,947 2.38%
Sector Bio Therapeutic Drugs